Acadia Pharmaceuticals – Product Catalog (A–Z)
Approved Medicines
-
DAYBUE® → Generic: trofinetide → Indication: Rett syndrome (first FDA-approved therapy) → Dose: Oral solution; weight-based dosing
-
NUPLAZID® → Generic: pimavanserin → Indication: Hallucinations and delusions associated with Parkinson’s disease psychosis → Dose: Tablets (34 mg capsule; also 10 mg for certain cases)
Investigational Pipeline
-
ACP-204 (Remlifanserin) → Next-generation 5-HT2A inverse agonist → Indication: Alzheimer’s disease psychosis, Lewy body dementia → Phase III development
-
ACP-101 → Investigational therapy for Prader-Willi syndrome → Late-stage clinical development
No comments:
Post a Comment